Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in <i>RAS</i> Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). 31578276 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models. 30973663 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. 30621206 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Although Daple acts as a tumor suppressor in the healthy colon, the concurrent increased abundance of Daple and epidermal growth factor receptor (EGFR) in colorectal tumors was associated with poor patient prognosis. 29487190 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE This critique briefly addressed EGFR receptor characteristics, worldwide report on various cancers and EGFR based potential targeting modalities in skin, breast, ovary, brain, lungs, pancreas, gastric and colorectal tumors and molecular pathways involved in EGFR targeting. 29991287 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Our aim was to characterize the mutational and expression profiles of the EGFR pathway in colorectal tumors and to integrate these results according to five previously defined groups. 28936923 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE We screened human colorectal tumors for EGFR-positive myeloid cells and investigated their association with patient outcome. 28400195 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group BEFREE We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and track clonal evolution during treatment with the epidermal growth factor receptor (EGFR)-specific antibodies cetuximab or panitumumab. 26030179 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Colorectal tumors evade EGFR blockade by constitutive activation of downstream signaling effectors and through mutations affecting receptor-antibody binding. 25623215 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE The failure of EGFR inhibitors in colorectal tumors with KRAS mutations requires the development of alternative treatment strategies for this patient subgroup. 24351336 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Three different macroscopic subtypes of colorectal neoplasms display distinct carcinogenetic pathways in EGFR networking. 25551625 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. 22990113 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE Using two mouse models of colitis-associated cancer, we found that epidermal growth factor receptor inactivation accelerated the incidence and progression of colorectal tumors. 22772467 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group BEFREE The EGFR expression levels on colorectal tumors were determined by ex vivo immunoblotting and ELISA. 22126621 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 GeneticVariation group CLINVAR Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. 22270724 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type colorectal tumors. 21701884 2011
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. 20563247 2010
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group LHGDN Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. 19033715 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE In addition, among colorectal tumors carrying wild-type KRAS, mutation of BRAF or PIK3CA or loss of PTEN expression may be associated with resistance to EGFR-targeted monoclonal antibody treatment, although these additional biomarkers require further validation before incorporation into clinical practice. 19738166 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE K-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies. 19712476 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Finally, circulating TGF-alpha increased in the plasma of six patients with EGFR-negative colorectal tumors during cetuximab treatment. 19276250 2009
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 AlteredExpression group LHGDN Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. 18245533 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group BEFREE Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. 18802721 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group CTD_human Panitumumab: in metastatic colorectal cancer with wild-type KRAS. 18998757 2008
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.500 Biomarker group LHGDN EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. 18154448 2008